# Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00083122** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
- Stage IIIA Ovarian Epithelial Cancer
- Stage IIIA Primary Peritoneal Cavity Cancer
- Stage IIIB Ovarian Epithelial Cancer
- Stage IIIB Primary Peritoneal Cavity Cancer
- Stage IIIC Ovarian Epithelial Cancer
- Stage IIIC Primary Peritoneal Cavity Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** alvocidib
- **DRUG:** cisplatin/flavopiridol

## Key facts

- **NCT ID:** NCT00083122
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2010-07
- **Final completion:** 2012-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083122, "Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00083122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*